DGAP-News: HAEMATO AG / Key word(s): Quarterly / Interim Statement/Half Year Results
HAEMATO AG: Half Year Report 2018
24.08.2018 / 17:11
The issuer is solely responsible for the content of this announcement.
In the first half of 2018, the HAEMATO Group increased sales by 3.6 % year-on-year to a total of EUR 143.7 million.
EBIT amounted to kEUR 6,484.6 (prior year period: kEUR 3,182.8).
The consolidated profit as of 30.06.2018 amounts to kEUR 5,044.5 and is therefore also significantly above the comparable previous year's value of 30 June 2017 to the amount of kEUR 2,164.
24.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Haemato AG, previously Windsor AG, is a Germany-based pharmaceutical company. The Company trades and patent-free and patent-protected medicines and generic drugs with focus on oncology, human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS), neurology, rheumatology, urology, cardiovascular diseases and other chronic diseases. The Company's main markets are Europe, North America and Japan. It also imports medicines from within the European Economic Area in form of parallel imports and re-imports. The Company's subsidiaries are Haemato Pharm GmbH, Heamato Med GmbH, Castell Pharma BV, Sanate GmbH and Heamato Asia Co Ltd. Customers can order medicine through phone, fax and e-mail, among others.